ESR1 and breast cancer: Tan et al. 2023 in their research compared the composition, organization, and intended application of ECM obtained from two genetic subtypes of breast cancer: TNBC (very aggressive, ERα-)-derived ECM (TN-ECM) and luminal-A breast cancer (less aggressive, ERα+)-derived ECM (LA-ECM).